These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


330 related items for PubMed ID: 17848374

  • 21. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J.
    Clin Infect Dis; 2008 Jan 15; 46(2):193-200. PubMed ID: 18171250
    [Abstract] [Full Text] [Related]

  • 22. Future strategies for treating Staphylococcus aureus bloodstream infections.
    Naber CK.
    Clin Microbiol Infect; 2008 Mar 15; 14 Suppl 2():26-34. PubMed ID: 18226087
    [Abstract] [Full Text] [Related]

  • 23. Management of methicillin-resistant Staphylococcus aureus bacteremia.
    Cosgrove SE, Fowler VG.
    Clin Infect Dis; 2008 Jun 01; 46 Suppl 5():S386-93. PubMed ID: 18462094
    [Abstract] [Full Text] [Related]

  • 24. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW, Patron RL, Goldstein BP, Archer GL.
    Antimicrob Agents Chemother; 1998 Jun 01; 42(6):1355-60. PubMed ID: 9624475
    [Abstract] [Full Text] [Related]

  • 25. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006.
    Laupland KB, Ross T, Gregson DB.
    J Infect Dis; 2008 Aug 01; 198(3):336-43. PubMed ID: 18522502
    [Abstract] [Full Text] [Related]

  • 26. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
    Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2002 Dec 01; 43(12):3712-6. PubMed ID: 12454041
    [Abstract] [Full Text] [Related]

  • 27. MRSA bacteraemia.
    Gould IM.
    Int J Antimicrob Agents; 2007 Nov 01; 30 Suppl 1():S66-70. PubMed ID: 17875386
    [Abstract] [Full Text] [Related]

  • 28. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
    Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW.
    Clin Infect Dis; 2009 Aug 01; 49(3):395-401. PubMed ID: 19569970
    [Abstract] [Full Text] [Related]

  • 29. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar 01; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis.
    Joosten U, Joist A, Gosheger G, Liljenqvist U, Brandt B, von Eiff C.
    Biomaterials; 2005 Sep 01; 26(25):5251-8. PubMed ID: 15792552
    [Abstract] [Full Text] [Related]

  • 31. Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital.
    Nulens E, Broex E, Ament A, Deurenberg RH, Smeets E, Scheres J, van Tiel FH, Gordts B, Stobberingh EE.
    J Hosp Infect; 2008 Apr 01; 68(4):301-7. PubMed ID: 18353496
    [Abstract] [Full Text] [Related]

  • 32. [Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections].
    Bernard P, Jarlier V, Santerre-Henriksen A.
    Ann Dermatol Venereol; 2008 Jan 01; 135(1):13-9. PubMed ID: 18342068
    [Abstract] [Full Text] [Related]

  • 33. MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.
    Desbois AP, Sattar A, Graham S, Warn PA, Coote PJ.
    J Antimicrob Chemother; 2013 Nov 01; 68(11):2569-75. PubMed ID: 23800902
    [Abstract] [Full Text] [Related]

  • 34. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED.
    Viallon A, Marjollet O, Berthelot P, Carricajo A, Guyomarc'h S, Robert F, Zeni F, Bertrand JC.
    Am J Emerg Med; 2007 Oct 01; 25(8):880-6. PubMed ID: 17920971
    [Abstract] [Full Text] [Related]

  • 35. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC.
    Int J Antimicrob Agents; 2007 Nov 01; 30(5):398-408. PubMed ID: 17888634
    [Abstract] [Full Text] [Related]

  • 36. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic.
    Oldham ER, Daley MJ.
    J Dairy Sci; 1991 Dec 01; 74(12):4175-82. PubMed ID: 1787188
    [Abstract] [Full Text] [Related]

  • 37. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM, Kokai-Kun JF.
    Antimicrob Agents Chemother; 2005 Aug 01; 49(8):3256-63. PubMed ID: 16048934
    [Abstract] [Full Text] [Related]

  • 38. Vancomycin: does it still have a role as an antistaphylococcal agent?
    Deresinski S.
    Expert Rev Anti Infect Ther; 2007 Jun 01; 5(3):393-401. PubMed ID: 17547504
    [Abstract] [Full Text] [Related]

  • 39. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC, Foster-Frey J, Donovan DM.
    FEMS Microbiol Lett; 2008 Oct 01; 287(2):185-91. PubMed ID: 18721148
    [Abstract] [Full Text] [Related]

  • 40. Staphylococcus aureus bloodstream infections: definitions and treatment.
    Corey GR.
    Clin Infect Dis; 2009 May 15; 48 Suppl 4():S254-9. PubMed ID: 19374581
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 17.